Literature DB >> 22136089

Comparison of human ocular distribution of bimatoprost and latanoprost.

Parul Ichhpujani1, L Jay Katz, Gabor Hollo, Carol L Shields, Jerry A Shields, Brian Marr, Ralph Eagle, Heryberto Alvim, Sheryl S Wizov, Andrew Acheampong, June Chen, Larry A Wheeler.   

Abstract

PURPOSE: This study investigated the ocular distribution of bimatoprost, latanoprost, and their acid hydrolysis products in the aqueous humor, cornea, sclera, iris, and ciliary body of patients treated with a single topical dose of 0.03% bimatoprost or 0.005% latanoprost for understanding concentration-activity relationships.
METHODS: Thirty-one patients undergoing enucleation for an intraocular tumor not affecting the anterior part of the globe were randomized to treatment with bimatoprost or latanoprost at 1, 3, 6 or 12 h prior to surgery. Concentrations of bimatoprost, bimatoprost acid, latanoprost, and latanoprost acid in the human aqueous and ocular tissues were measured using liquid chromatography tandem mass spectrometry.
RESULTS: Following topical administration, intact bimatoprost was distributed in human eyes with a rank order of cornea/sclera >iris/ciliary body >aqueous humor. Bimatoprost acid was also detected in these tissues, where its low levels in the cornea relative to that of latanoprost acid indicated that bimatoprost hydrolysis was limited. Latanoprost behaved as a prodrug that entered eyes predominantly via the corneal route. Levels of latanoprost acid were distributed as cornea >>aqueous humor>iris>sclera>ciliary body.
CONCLUSIONS: Our study provided experimental evidence that levels of bimatoprost in relevant ocular tissues, and not only aqueous humor, are needed to understand the mechanisms by which bimatoprost lowers intraocular pressure (IOP) in human subjects. The data suggest that bimatoprost reached the target tissues favoring the conjunctival/scleral absorption route. Findings of intact bimatoprost in the target ciliary body indicated its direct involvement in reducing IOP. However, bimatoprost acid may have only a limited contribution on the basis that bimatoprost has greater/similar IOP-lowering efficacy than latanoprost, yet bimatoprost acid levels were a fraction of latanoprost acid levels in the aqueous humor and cornea and only sporadically detectable in the ciliary body. In this report, human ocular tissues were examined concurrently with aqueous humor for the in vivo distribution of bimatoprost, bimatoprost acid, latanoprost, and latanoprost acid.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136089     DOI: 10.1089/jop.2011.0097

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  8 in total

1.  Effects of prostaglandin F(2α) on adipocyte biology relevant to graves' orbitopathy.

Authors:  Mohd Shazli Draman; Fiona Grennan-Jones; Lei Zhang; Peter N Taylor; Tommy Kyaw Tun; John McDermott; Paul Moriarty; Daniel Morris; Carol Lane; Seamus Sreenan; Colin Dayan; Marian Ludgate
Journal:  Thyroid       Date:  2013-11-04       Impact factor: 6.568

2.  Outflow facility efficacy of five drugs in enucleated porcine eyes by a method of constant-pressure perfusion.

Authors:  Ning Li; Hui-Min Shi; Lin Cong; Zhao-Zeng Lu; Wen Ye; Yu-Yan Zhang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

3.  Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.

Authors:  Kaidi Wang; Li Xu; Zhilan Yuan; Ke Yao; Junmei Zhao; Liang Xu; Aiwu Fang; Mingzhi Zhang; Lingling Wu; Jian Ji; Jiamin Hou; Qing Liu; Xinghuai Sun
Journal:  BMC Ophthalmol       Date:  2014-02-25       Impact factor: 2.209

4.  A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits.

Authors:  Françoise Brignole-Baudouin; Nicolas Desbenoit; Gregory Hamm; Hong Liang; Jean-Pierre Both; Alain Brunelle; Isabelle Fournier; Vincent Guerineau; Raphael Legouffe; Jonathan Stauber; David Touboul; Maxence Wisztorski; Michel Salzet; Olivier Laprevote; Christophe Baudouin
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

5.  Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes.

Authors:  Afshin Shafiee; Lyle M Bowman; Eddie Hou; Kamran Hosseini
Journal:  Clin Ophthalmol       Date:  2013-07-31

6.  Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy.

Authors:  Takako Miki; Tomoko Naito; Miyuki Fujiwara; Ryoichi Araki; Rieko Kiyoi; Yusuke Shiode; Atsushi Fujiwara; Yuki Morizane; Fumio Shiraga
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

7.  Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.

Authors:  Jennifer R Seal; Michael R Robinson; James Burke; Marina Bejanian; Michael Coote; Mayssa Attar
Journal:  J Ocul Pharmacol Ther       Date:  2018-10-18       Impact factor: 2.671

Review 8.  Matrix Metalloproteinases and Glaucoma Treatment.

Authors:  Robert N Weinreb; Michael R Robinson; Mohammed Dibas; W Daniel Stamer
Journal:  J Ocul Pharmacol Ther       Date:  2020-04-01       Impact factor: 2.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.